Plaquenil is primarily prescribed as a long-term treatment for autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). In these conditions, the immune system mistakenly attacks the body’s own tissues, leading to chronic pain, swelling, fatigue, and organ involvement. Plaquenil helps by modulating immune activity rather than suppressing it completely, which is why it is categorized as a disease-modifying antirheumatic drug. Over time, this immune modulation can decrease flare frequency, protect joints and organs, and improve overall function and quality of life.
Beyond lupus and rheumatoid arthritis, Plaquenil is sometimes used for other rheumatologic and dermatologic conditions such as discoid lupus, certain forms of inflammatory arthritis, and some autoimmune skin rashes. It may also be part of combination therapy when patients do not respond adequately to a single medication. In malaria-endemic regions or for travelers, hydroxychloroquine has historically been used for malaria prophylaxis and treatment of specific Plasmodium species, though resistance patterns and guidelines vary by location and over time.
Clinically, Plaquenil is valued because it can reduce symptoms like joint stiffness and rash without the same level of infection risk associated with stronger immunosuppressants or high-dose steroids. However, its onset of action is slow; many patients need several weeks to months before noticing full benefits. Plaquenil is generally used as a maintenance medication, taken daily to keep disease activity under control, rather than as a quick fix for acute flares.
In addition to symptom relief, research suggests Plaquenil may provide longer-term protective effects, especially in lupus. Studies have linked regular Plaquenil use to lower flare rates, reduced risk of blood clots, and possibly improved survival in some lupus patients. Because autoimmune diseases often require lifelong management, Plaquenil is frequently part of a comprehensive care plan that may include other medications, lifestyle changes, and regular monitoring by rheumatologists or internal medicine specialists.
Plaquenil is available as oral tablets, most commonly in a 200 mg strength. Typical daily doses for adults with autoimmune diseases range from 200 mg to 400 mg, taken once daily or divided into two doses. The exact dose depends on body weight, diagnosis, disease activity, and overall risk profile, including eye health. Many clinicians aim to keep the daily dose at or below 5 mg of hydroxychloroquine per kilogram of real body weight, as higher long-term doses are associated with increased retinal toxicity risk.
Plaquenil should be taken with food or a glass of milk to reduce stomach upset, nausea, or abdominal discomfort. The tablets should be swallowed whole with water and not crushed unless your healthcare provider advises otherwise. Consistency is crucial: taking the medication at the same time each day helps maintain stable blood levels and supports long-term disease control. Patients should not adjust their dose, split tablets, or stop treatment abruptly without consulting their healthcare professional.
When Plaquenil is used for lupus or rheumatoid arthritis, it often takes 4 to 12 weeks for noticeable improvement in symptoms like pain, stiffness, and fatigue. Because the onset is gradual, some patients may feel discouraged early on and be tempted to discontinue therapy. It is important to continue as directed, as stopping too soon can prevent the full therapeutic effect and may risk disease flares. Healthcare providers often schedule follow-up appointments several weeks after initiation to evaluate tolerance and early response.
For malaria prevention or treatment, dosing regimens are different and usually short-term. Prophylaxis often begins one to two weeks before travel and continues for a specified period after leaving the endemic area, while treatment courses are typically brief and combined with other antimalarials, depending on local guidelines. Because resistance patterns change and dosing for malaria requires precision, these regimens must be determined by a qualified clinician or travel medicine specialist rather than self-directed use.
Before starting Plaquenil, patients should provide a complete medical history, including eye problems, heart disease, kidney or liver impairment, neurologic disorders, psoriasis, blood disorders, and any history of serious drug reactions. A baseline eye examination with an ophthalmologist is strongly recommended, especially for individuals expected to be on Plaquenil for more than five years. This exam typically includes visual field testing and imaging of the retina to document initial eye health and detect any preexisting abnormalities.
Because long-term Plaquenil use can rarely cause retinal damage, ongoing eye monitoring is a key precaution. For most patients, formal screening begins after five years of continuous use, but those at higher risk—such as individuals taking higher doses, with kidney disease, or preexisting retinal disorders—may need earlier and more frequent checks. Patients should report any visual changes immediately, including difficulty focusing, blurred vision, blind spots, or color vision changes, as early detection can prevent permanent vision loss.
Cardiac precautions are also important. Hydroxychloroquine can, in rare cases, affect heart rhythm, especially when combined with other drugs that prolong the QT interval or in patients with existing heart conditions. Those with a history of arrhythmias, heart failure, or cardiomyopathy should be assessed carefully, and in some situations, baseline and periodic electrocardiograms (ECGs) may be recommended. Patients who experience palpitations, dizziness, fainting spells, or unexplained shortness of breath while on Plaquenil should seek medical evaluation promptly.
Pregnancy and breastfeeding require individualized risk–benefit discussions. For many women with lupus or rheumatoid arthritis, continuing Plaquenil during pregnancy is considered safer than allowing disease to flare, as uncontrolled autoimmune activity can harm both mother and baby. Many guidelines support its use in pregnancy and lactation under specialist supervision. However, all decisions should be made collaboratively, weighing disease severity, alternative options, and the latest clinical evidence to protect maternal and fetal health.
Plaquenil is contraindicated in individuals with a known hypersensitivity or allergy to hydroxychloroquine, chloroquine, or any of the tablet’s inactive components. Symptoms of prior severe reaction can include rash, swelling, difficulty breathing, or anaphylaxis. Patients who have experienced these events after taking similar antimalarial or antirheumatic drugs should not use Plaquenil again unless a specialist has carefully reviewed the case and determined it is safe.
Significant preexisting retinal disease or macular degeneration is another major contraindication or strong caution area. Since Plaquenil can, in rare cases, induce retinal toxicity with prolonged use, adding it in the context of already damaged or vulnerable retinas significantly increases the risk of permanent vision impairment. Ophthalmologists and rheumatologists often jointly decide whether Plaquenil is appropriate in such cases and may recommend alternative therapies when the risk outweighs the benefit.
Severe renal or hepatic impairment may also limit Plaquenil use. The drug is processed and cleared partly through the liver and kidneys, so serious dysfunction can lead to accumulation and heightened toxicity risk, including eye, heart, and neurologic complications. In some patients, careful dose adjustment and close monitoring may be possible, but in others, Plaquenil may be avoided altogether. This is why baseline kidney and liver function tests are commonly ordered before and during therapy.
Additional relative contraindications or caution situations include certain blood disorders, psoriasis that worsens with antimalarial drugs, and preexisting neurologic conditions such as epilepsy. In these scenarios, Plaquenil might still be used when benefits clearly outweigh risks, but only with specialist oversight and a clear monitoring plan. Patients should never self-initiate Plaquenil if they have complex medical histories without obtaining professional guidance and a clear green light from their care team.
Most people tolerate Plaquenil reasonably well, especially at standard doses, but side effects can occur. Common, usually mild reactions include nausea, stomach cramps, loss of appetite, and diarrhea. These gastrointestinal symptoms often improve when the medication is taken with food and may lessen as the body adjusts over time. Mild headache, dizziness, or tiredness can also appear initially and may respond to simple measures such as hydration, rest, or dose timing adjustments recommended by a clinician.
Skin reactions are another possible side effect. Some patients develop mild rashes, itching, or increased sensitivity to sunlight while on Plaquenil. Using sunscreen, wearing protective clothing, and avoiding prolonged direct sun exposure can help reduce photosensitivity reactions. However, sudden, widespread rashes, blistering, or peeling of the skin may indicate a more serious drug reaction that requires immediate medical attention and likely discontinuation of the medication under professional supervision.
More serious but less common side effects include changes in vision, which may signal retinal toxicity. Symptoms to watch for include difficulty reading, blurry or dim vision, shadows or blank spots in the visual field, or trouble distinguishing colors. Because retinal damage may be irreversible if not caught early, any such changes warrant urgent evaluation by an eye specialist and prompt communication with the prescribing provider. The overall risk of vision damage is strongly influenced by dose, duration of therapy, and individual risk factors.
Rare systemic adverse events have also been reported, including blood disorders (like low white cells or platelets), severe muscle weakness, cardiomyopathy, and dangerous heart rhythm changes. Sudden chest pain, unexplained shortness of breath, rapid or irregular heartbeat, fainting, severe muscle pain, or unusual bruising or bleeding should be treated as urgent warning signs. Patients and caregivers should be educated about these potential serious side effects before starting Plaquenil so they can recognize early symptoms and seek timely care.
Plaquenil can interact with a variety of medications, altering either its own effectiveness or the safety profile of other drugs. One important category is medicines that affect heart rhythm, particularly those that prolong the QT interval on an ECG. Combining Plaquenil with certain antiarrhythmics, some antidepressants, antipsychotics, or specific antibiotics can elevate the risk of dangerous arrhythmias. For patients who must take such combinations, careful risk assessment, baseline and follow-up ECGs, and electrolyte monitoring may be necessary.
Hydroxychloroquine may also influence blood sugar levels, sometimes lowering them, which is particularly relevant for individuals with diabetes. When Plaquenil is added to a regimen that includes insulin or oral diabetes medications, the risk of hypoglycemia may increase. Patients should monitor their blood glucose closely after starting Plaquenil or changing the dose, and clinicians may need to adjust diabetes therapy accordingly to maintain safe, stable glucose control.
Other notable interactions include effects on drugs like digoxin, certain antiepileptic agents, and medications that affect liver enzymes. Plaquenil can raise blood levels of digoxin, potentially causing toxicity, so digoxin doses and blood levels may require more frequent monitoring. With antiepileptics, hydroxychloroquine can rarely lower seizure threshold, and careful observation is advised. As with many systemic medications, Plaquenil’s metabolism can be influenced by other drugs that induce or inhibit hepatic enzymes, which may alter its concentration and side effect risk.
Because the interaction profile can be complex, patients should provide a complete list of prescriptions, over-the-counter medications, herbal supplements, and vitamins before starting Plaquenil. This list should be kept up to date, with any changes shared promptly with the prescribing clinician or pharmacist. Self-medicating, especially with heart, psychiatric, or seizure medications, while on Plaquenil is risky and should be avoided without professional review of potential drug–drug interactions.
If a patient misses a scheduled dose of Plaquenil, the general advice is to take the dose as soon as it is remembered, unless it is very close to the time of the next dose. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the patient should simply resume the usual dosing schedule. Doubling up on doses to compensate for a missed tablet is not recommended, as it can lead to higher short-term drug levels and increase the likelihood of side effects such as nausea, dizziness, or cardiac rhythm disturbances.
Occasional missed doses are unlikely to cause immediate disease flare because Plaquenil works cumulatively over time. However, frequent missed doses can reduce treatment effectiveness, potentially allowing autoimmune activity to rise and symptoms to return. Patients who find themselves forgetting Plaquenil regularly may benefit from practical strategies such as setting phone reminders, pairing the medication with a daily routine like breakfast, or using pill organizers. If adherence is consistently difficult, discussing this openly with a healthcare provider can help identify barriers and alternative approaches.
Plaquenil overdose is a medical emergency and can be life-threatening, even in relatively small amounts, particularly for children. Symptoms of hydroxychloroquine overdose may develop rapidly and can include severe dizziness, headache, visual disturbances, nausea, vomiting, seizures, dangerously low blood pressure, abnormal heart rhythms, and cardiac arrest. Because the onset of toxicity can be swift, immediate medical attention is critical if an overdose is suspected, regardless of whether symptoms are already present.
If someone has taken more Plaquenil than prescribed or a child has accidentally ingested tablets, emergency services should be contacted at once, and the local poison control center should be notified for guidance. Do not wait to see if symptoms appear or attempt home remedies. In a hospital setting, treatment may involve cardiac monitoring, supportive care for breathing and blood pressure, management of seizures, and the use of specific medications to stabilize the heart rhythm. Prompt intervention significantly improves the chances of survival and reduces the risk of long-term complications.
Proper storage of Plaquenil helps maintain its potency and reduces the risk of accidental ingestion, especially in households with children or pets. The tablets should be stored at room temperature, typically between 68°F and 77°F (20°C to 25°C), away from excess heat, moisture, and direct sunlight. Bathrooms and kitchen areas near sinks are usually not ideal storage locations because of humidity and temperature fluctuations.
Plaquenil should always be kept in its original container or in a clearly labeled prescription bottle with a child-resistant cap. The container must be stored out of reach and out of sight of children, as even a few tablets can be dangerous if swallowed accidentally. Patients should also avoid transferring tablets into unlabeled containers or pillboxes that could be confused with other medications unless they maintain clear labeling and understand the dosing schedule. Expired or unused Plaquenil should be disposed of safely according to pharmacy or local regulations, rather than thrown into household trash where it could be found by children or animals.
In the United States, Plaquenil is a prescription-only medication due to its powerful effects on the immune system and the potential for serious side effects if misused. Federal and state regulations require that hydroxychloroquine be prescribed by a licensed healthcare professional who can evaluate the patient’s condition, rule out contraindications, and arrange appropriate monitoring, including periodic eye examinations. Pharmacies are obligated to dispense Plaquenil only in accordance with valid prescriptions and applicable laws, which are designed to protect patient safety and promote responsible use.
Because of these regulations, purchasing Plaquenil without a traditional prescription from unverified sources, including some online vendors, poses significant risks. Such channels may provide counterfeit, substandard, or incorrectly dosed products, and they often lack the clinical oversight necessary for safe use. In addition, bypassing medical evaluation can delay diagnosis of underlying conditions, omit essential monitoring for retinal or cardiac effects, and increase the chance of harmful drug interactions and overdoses.
HealthSouth Rehabilitation Hospital of Columbia offers a legal and structured solution for individuals seeking to buy Plaquenil without prescription in the usual sense. Instead of informal or unsupervised access, the hospital uses integrated clinical pathways in which patients are evaluated by qualified professionals who assess disease status, review current medications, and determine whether Plaquenil is appropriate. Within this framework, patients can obtain Plaquenil through streamlined institutional protocols that meet regulatory requirements while simplifying access and emphasizing safety.
This model balances convenience with medical oversight. Patients benefit from supervised dosing plans, ongoing monitoring for side effects, and coordinated care among rheumatologists, internists, ophthalmologists, and pharmacists. By choosing a regulated setting like HealthSouth Rehabilitation Hospital of Columbia, individuals who need Plaquenil for conditions such as lupus or rheumatoid arthritis can avoid the hazards of unregulated online vendors, ensure they receive authentic medication, and gain access to expert guidance for long-term disease management and risk reduction.
Plaquenil (generic name: hydroxychloroquine) is a prescription medication originally developed to prevent and treat malaria. Today, it is more commonly used as a disease-modifying antirheumatic drug (DMARD) to treat autoimmune conditions like rheumatoid arthritis, systemic lupus erythematosus (SLE), discoid lupus, and some other inflammatory conditions. It helps reduce pain, swelling, and long-term joint and organ damage.
Plaquenil works by modulating the immune system rather than completely suppressing it. It interferes with how immune cells process and present antigens, reduces inflammatory signaling, and stabilizes certain immune pathways. This helps decrease autoimmunity—the process by which the immune system mistakenly attacks healthy tissues—thereby reducing inflammation, pain, and flares over time.
Plaquenil is not a fast-acting medication. For autoimmune conditions, most people start to notice some improvement after 4–6 weeks, but it can take 3–6 months to see the full benefit. Because of this delayed onset, doctors often pair Plaquenil with faster-acting medications early in treatment while waiting for its disease-modifying effects.
Common side effects include nausea, stomach pain, diarrhea, decreased appetite, headache, dizziness, skin rash, and mild hair thinning. Many of these improve over time or with dose adjustments, taking the medication with food, or splitting the dose. Always report persistent or bothersome side effects to your healthcare provider.
Yes. The most serious long-term risk of Plaquenil is retinal toxicity, which can damage the macula (the central part of the retina) and lead to vision changes or permanent vision loss in severe cases. This risk is related to the dose, length of time on the drug, kidney function, and other factors. With proper dosing and regular eye exams, the risk is low, but it is not zero.
Most guidelines recommend a baseline comprehensive eye exam within the first year of starting Plaquenil. If your dose is appropriate and you have no major risk factors, screening is usually repeated annually starting after 5 years of continuous use. People at higher risk (high doses, kidney disease, pre-existing retinal disease, long-term use beyond 5 years) may need earlier and more frequent exams. Follow your eye doctor’s specific recommendations.
Risk is higher if you take a daily dose exceeding about 5 mg per kilogram of real body weight, use Plaquenil for more than 5 years, have kidney disease, pre-existing retinal or macular disease, are older, or take certain additional medications that affect the retina. Careful dosing and regular ophthalmologic monitoring significantly reduce the likelihood of serious problems.
Call your doctor promptly if you notice blurred or distorted central vision, difficulty reading, trouble seeing faces clearly, new blank or dark spots in your central vision, changes in color vision, or increased sensitivity to light. Do not wait for your next routine appointment if you notice these changes; early detection is crucial.
Plaquenil is often considered relatively safe in pregnancy and breastfeeding, and many rheumatologists and obstetricians recommend continuing it to keep lupus or rheumatoid arthritis under control, because uncontrolled disease can be more dangerous than the medication itself. However, decisions are individualized. Always discuss family planning, pregnancy, and breastfeeding with your prescribing physician before starting or stopping Plaquenil.
Plaquenil does not usually require as intensive blood test monitoring as some other DMARDs, but baseline and periodic blood tests are common. Your doctor may monitor your blood counts, liver function, kidney function, and, in some cases, muscle enzymes. The frequency depends on your overall health, other medications, and underlying disease.
Rarely, Plaquenil can affect the heart, potentially causing cardiomyopathy (heart muscle weakness) or changes in heart rhythm (like QT prolongation). This is uncommon, but risk increases with high doses, long-term use, pre-existing heart disease, or combination with other QT-prolonging drugs. Report symptoms such as shortness of breath, chest discomfort, palpitations, unexplained swelling, or fainting spells.
Yes. Plaquenil can interact with medications that affect heart rhythm (like some antiarrhythmics, certain antibiotics, and some antidepressants), other drugs that lower blood sugar, seizure medications, digoxin, and some antacids that may interfere with absorption. Always provide a full list of prescription medications, over-the-counter drugs, vitamins, and herbal supplements to your doctor and pharmacist.
Plaquenil can occasionally lower blood sugar levels, and there have been reports of hypoglycemia (low blood sugar), even in people without diabetes. People with diabetes may need adjustment of their diabetes medications when starting Plaquenil. Watch for symptoms such as shaking, sweating, confusion, dizziness, or fast heartbeat and report them promptly.
Plaquenil is sometimes used because it can actually help reduce skin sensitivity to sunlight in conditions like lupus. However, some people still develop photosensitivity or rashes. It remains important to use sun protection: wear sunscreen, protective clothing, hats, and avoid peak sun exposure when possible, especially if you have a photosensitive condition.
Plaquenil does not cause physical dependence, so it can be stopped without tapering from a pharmacologic standpoint. However, abruptly stopping it may lead to a flare of your autoimmune disease. Never stop hydroxychloroquine on your own; always discuss with your rheumatologist or prescribing doctor, who will weigh risks and may adjust other medications if needed.
No, Plaquenil is not a steroid. It is an antimalarial medication used as a disease-modifying antirheumatic drug. It does not cause the typical steroid side effects such as fluid retention, major weight gain, or bone thinning. Some people might experience mild appetite changes or digestive issues, but these are usually modest compared to steroid effects.
Plaquenil can be used as monotherapy in mild rheumatoid arthritis or lupus, but it is often combined with other DMARDs or biologic agents for moderate to severe disease. Combination therapy can improve symptom control and reduce flares. Common combinations include Plaquenil with methotrexate, sulfasalazine, or biologic drugs. Your treatment plan is individualized based on disease severity and response.
If you miss a dose and remember on the same day, take it as soon as you remember, unless it is almost time for your next dose. If it is close to the next dose, skip the missed one and take your next dose at the regular time. Do not double up doses to “make up” for a missed tablet. If you frequently forget doses, talk to your doctor or pharmacist about strategies to improve adherence.
No medication is right for everyone. Plaquenil may not be suitable for people with certain retinal diseases, severe liver or kidney impairment, certain heart rhythm problems, known allergy to hydroxychloroquine or chloroquine, or a history of serious adverse reactions to antimalarials. Your doctor will review your medical history, current medications, exam findings, and test results before prescribing it.
Yes. Beyond rheumatoid arthritis and lupus, Plaquenil is sometimes used for Sjögren’s syndrome, some inflammatory skin diseases (such as cutaneous lupus or certain photosensitive rashes), and other off-label autoimmune or inflammatory conditions when a clinician believes the benefits may outweigh the risks. Evidence and guidelines vary by condition, so these uses are individualized.
Plaquenil and methotrexate are both DMARDs, but methotrexate is generally considered more potent for controlling moderate to severe rheumatoid arthritis. Methotrexate often works faster and more strongly, but it can have more significant potential side effects, including liver toxicity, bone marrow suppression, and lung inflammation. Plaquenil is usually better tolerated, does not require as intensive lab monitoring, and does not typically cause severe immunosuppression. In practice, they are often used together to maximize benefit while balancing safety.
“Safer” depends on the specific risk being considered. Plaquenil has a generally favorable safety profile, with a lower risk of serious infections, liver damage, or bone marrow suppression compared with methotrexate. However, Plaquenil carries a unique risk of retinal toxicity, especially with long-term high-dose use. Methotrexate does not cause retinal damage but demands regular blood monitoring and strict precautions regarding alcohol and pregnancy. Your doctor will help decide which is safer for you personally.
Plaquenil (hydroxychloroquine) and chloroquine are closely related antimalarial drugs. Hydroxychloroquine is generally considered safer, particularly concerning eye and heart toxicity, which is why it is preferred for long-term use in autoimmune diseases. Chloroquine is less commonly used now in rheumatology because its side effect profile is more concerning at equivalent doses, especially for the retina.
Doctors typically choose Plaquenil over chloroquine because hydroxychloroquine has a better safety profile, especially with regard to retinal toxicity and overall tolerance for long-term use. Many clinical guidelines specifically recommend hydroxychloroquine as a first-line antimalarial DMARD for lupus and rheumatoid arthritis, reserving chloroquine for specific situations where hydroxychloroquine is not available or suitable.
Both Plaquenil and sulfasalazine are conventional DMARDs used in rheumatoid arthritis and some inflammatory conditions. Plaquenil tends to have fewer gastrointestinal and hematologic side effects but requires eye monitoring. Sulfasalazine may act somewhat faster and can be more effective for some patients but may cause nausea, rash, low blood counts, or liver abnormalities and requires regular blood tests. They are often combined (sometimes with methotrexate) in a regimen known as “triple therapy” for RA.
Biologic medications (such as TNF inhibitors, IL-6 inhibitors, or B-cell–targeting agents) are generally more powerful than Plaquenil for moderate to severe rheumatoid arthritis or aggressive systemic lupus. Plaquenil is often used in mild disease or as a baseline therapy, while biologics are added if disease activity remains high. However, Plaquenil has advantages: it is taken orally, is less expensive, has fewer serious infection risks, and is frequently used in combination with biologics to improve outcomes.
Yes. Plaquenil is commonly combined with methotrexate, sulfasalazine, and various biologic or targeted synthetic DMARDs. Using Plaquenil as part of combination therapy can enhance disease control and may allow lower doses of other drugs. However, combined regimens should always be overseen by a rheumatologist, with appropriate monitoring for side effects and interactions.
Plaquenil is considered immunomodulatory rather than strongly immunosuppressive. It does not significantly lower white blood cell counts or cause frequent serious infections the way some other DMARDs and biologics can. That said, people with autoimmune diseases are already at higher infection risk, and many are on multiple medications, so infection precautions are still important.
Plaquenil’s main serious long-term risk is retinal toxicity, which can be minimized by staying within recommended dose limits and having regular eye exams. In contrast, drugs like methotrexate, leflunomide, or azathioprine carry higher risks of liver enzyme elevations, bone marrow suppression, and sometimes lung or other organ toxicities, requiring regular blood tests. Each drug’s risk profile is different; doctors weigh the potential for eye damage with Plaquenil against the hematologic and hepatic risks of alternative agents.
Leflunomide is typically more potent than Plaquenil for moderate to severe RA but can have more concerning side effects, including liver toxicity, high blood pressure, gastrointestinal issues, and teratogenicity (harm to a developing fetus). Plaquenil is often used for milder disease or in combination regimens, whereas leflunomide is reserved for patients needing stronger disease control and who can adhere to close monitoring and pregnancy precautions.
Plaquenil is often continued when a biologic is added because it may enhance the effectiveness of the biologic, help maintain disease remission, and has additional benefits such as reducing flares in lupus and potentially improving lipid and glucose profiles. Because its immunosuppressive effect is modest and it is generally well tolerated, many clinicians view Plaquenil as a useful “foundation” therapy.
In systemic lupus erythematosus, hydroxychloroquine is considered a cornerstone medication. It reduces disease activity, decreases flares, may protect against organ damage, and is associated with improved survival. Other DMARDs like methotrexate, azathioprine, or mycophenolate are added depending on which organs are involved and how severe the disease is. Plaquenil is recommended for nearly all lupus patients unless contraindicated.
Plaquenil and corticosteroids work very differently. Prednisone provides rapid, strong anti-inflammatory effects but carries significant long-term risks (weight gain, diabetes, osteoporosis, high blood pressure, infections, mood changes, cataracts). Plaquenil works slowly and is used to reduce the need for steroids over time. Many treatment plans use steroids for short-term control while Plaquenil and other DMARDs take effect, with the goal of lowering or stopping steroids when possible.
Sometimes. If you are experiencing troublesome side effects such as liver issues, frequent infections, or low blood counts on another DMARD, your doctor may consider switching to or adding Plaquenil, which is often better tolerated. However, if your disease is severe, Plaquenil alone may not provide enough control. Any switch requires careful discussion of disease activity, risks, and monitoring needs with your rheumatologist.